Leading integrated drug discovery, development, and manufacturing organization, Concept Life Sciences, has divested its Bradford analytical chemistry business to Cormica, the specialists in testing services for medical device and pharmaceutical manufacturers. Both Concept Life Sciences and Cormica are part of private equity house, Limerston Capital LLP, and form part of its healthcare portfolio.
The close relationship between the firms has allowed the deal to execute effortlessly and acknowledge the synergies between Bradford’s research and analytical expertise, particularly in analytical chemistry and materials characterizations, and Cormica’s existing capabilities in chemical analysis and physical testing of medical devices and combination products.
The divestment of the Bradford business represents a strategic move for Concept Life Sciences, enabling the company to sharpen its focus on its core service offerings, spanning drug discovery to early-stage development pathways. Established in 2017, Concept Life Sciences is recognized for its exceptional expertise in the pharmaceutical, biotech, and agrochemical sectors, extending across process research and development, manufacturing, and the team offers invaluable insights into rapidly evolving specialty therapeutic areas while fostering innovation.
The deal will include the transfer of all employees based at the Bradford site to Cormica. They will remain located at the Bradford office, and business will continue as normal. Cormica has recently undergone a significant brand exercise, aligning its new identity and name with the business’s end-to-end focus and plans to expand its footprint in the UK, US and Europe, bringing forward life-saving products more quickly, safely, and to more markets around the world.
Mark Hammond, CEO of Cormica, declared, “Cormica has an ambitious growth strategy, trained on full-service regulated testing across physical, chemical and microbiology. We know the Bradford business and its team well, and the opportunity to strengthen our expertise in analytical chemistry will significantly strengthen our market position, and provide an enhanced service to our customers. We are now looking forward to integrating the team into Cormica and to identifying the immediate opportunities this will bring.”
Ben Cliff, CEO of Concept Life Sciences, added, “It has been a busy year for the company, and we have had the much-needed chance to review our operations and longer-term strategy, which will help us to realize the company’s full potential. This deal will allow us to concentrate on our core service lines, working with our highly skilled team to drive our work in key markets.”